BioSpace News Archive

Drug Development

Reanalysis of Key Trial Flags Fresh Safety Concerns for Amgen’s Repatha (Updated)

Amgen’s Repatha may cause cardiac harm, according to a reassessment of the biologic’s late-stage trial data.

January 4, 2023
·
3 min read
·
Tristan Manalac
Business

BrainStorm Preps for Type A NurOwn Meeting, Shakes Up C-Suite

BrainStorm Cell Therapeutics appoints a new co-CEO as it prepares for a January 11th Type A meeting for ALS hopeful NurOwn.

January 4, 2023
·
3 min read
·
Heather McKenzie
Drug Development

Market Appears to Question Competitive Prospects of Vera’s IgAN Therapy

Vera Therapeutics’ stock crashed following the reveal of data from a Phase IIb study of atacicept in IgAN.

January 4, 2023
·
2 min read
·
Tristan Manalac
Business

Belharra Launches with $130M From Versant, Genentech to Advance Chemoproteomics Platform (Updated)

Backed by Versant and Genentech, Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform.

January 4, 2023
·
2 min read
·
Rosemary Scott
Drug Development

Geron Announces Positive Phase III Data, Likely to Seek FDA Approval in MDS

Geron announced Wednesday positive topline results from the Phase III IMerge trial evaluating the telomerase inhibitor, imetelstat, in lower-risk myelodysplastic syndromes patients.

January 4, 2023
·
2 min read
·
Lisa Munger
Executives Reunite at JPM as Biotech Kicks Off 2023

JP Morgan week is shaping up to approximate pre-pandemic attendance levels as executives return to San Francisco after two years of COVID-19-enforced absences.

January 4, 2023
·
5 min read
·
Gail Dutton
Drug Development

MD Anderson Delivers a Triple Punch to Pancreatic Cancer

In a recently published study, MD Anderson researchers achieved curative responses in pancreatic cancer models by targeting checkpoints in T cells and myeloid suppressor cells.

January 4, 2023
·
4 min read
·
Heather McKenzie
Job Trends

Press Release: Availability of the Q4 2022 Memorandum for modelling purposes

Sanofi announced that its Q4 2022 Memorandum for modelling purposes is available on the “Investors” page of the company’s website:

January 4, 2023
·
4 min read
Drug Development

Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors

Orano Med announced that the first patient has been dosed in a Phase 1 trial of the alpha radioligand therapy with lead-212, 212Pb-GRPR, in patients with advanced solid tumors that express gastrin-releasing peptide receptor.

January 4, 2023
·
4 min read
Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its second Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells.

January 4, 2023
·
2 min read